1. Home
  2. FBRT vs ABUS Comparison

FBRT vs ABUS Comparison

Compare FBRT & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin BSP Realty Trust Inc.

FBRT

Franklin BSP Realty Trust Inc.

HOLD

Current Price

$9.03

Market Cap

701.9M

Sector

Real Estate

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.16

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBRT
ABUS
Founded
2012
2005
Country
United States
United States
Employees
223
19
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
701.9M
848.8M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
FBRT
ABUS
Price
$9.03
$4.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$11.50
$5.00
AVG Volume (30 Days)
708.0K
1.6M
Earning Date
04-29-2026
05-14-2026
Dividend Yield
15.83%
N/A
EPS Growth
N/A
55.26
EPS
N/A
0.87
Revenue
N/A
$14,083,000.00
Revenue This Year
$12.34
N/A
Revenue Next Year
$4.95
$239.71
P/E Ratio
$13.56
$4.81
Revenue Growth
N/A
128.21
52 Week Low
$8.24
$3.04
52 Week High
$11.84
$5.10

Technical Indicators

Market Signals
Indicator
FBRT
ABUS
Relative Strength Index (RSI) 49.10 42.04
Support Level $8.91 $4.17
Resistance Level $9.26 $4.62
Average True Range (ATR) 0.22 0.15
MACD -0.01 -0.01
Stochastic Oscillator 39.53 23.96

Price Performance

Historical Comparison
FBRT
ABUS

About FBRT Franklin BSP Realty Trust Inc.

Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. The Company's operations are organized into two business units: (i) Commercial Real Estate Financing, and (ii) Agency Business. Its four reporting segments are as follows: The real estate debt business, The Agency Business, The commercial real estate conduit business, and The real estate owned business.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: